NextBioMedical Co

NextBioMedical Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is 220.39. In the previous year, Cash Conversion Cycle (CCC) was 331.79 — a change of -33.57% (lower).

Cash Conversion Cycle

220.39

YoY

-33.57%

Last updated:

Cash Conversion Cycle (CCC) of NextBioMedical Co is 2025 220.39 . Cash Conversion Cycle (CCC) of NextBioMedical Co was 2024 331.79 . It decreases by -33.57% lower compared to the previous year.

The NextBioMedical Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2021
165.23 KRW
Jan 1, 2022
326.34 KRW
Jan 1, 2023
354.49 KRW
Jan 1, 2024
331.79 KRW
Jan 1, 2025
220.39 KRW
The NextBioMedical Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
220.39-33.57%
331.79-6.40%
354.49+8.63%
326.34+97.51%
165.23—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Cash Conversion Cycle (CCC) of NextBioMedical Co is 220.39 in 2025.

Cash Conversion Cycle (CCC) of NextBioMedical Co changed from 331.79 to 220.39, representing a -33.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s NextBioMedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NextBioMedical Co

All Key Metrics — NextBioMedical Co